# 1. Financial Performance ## A. Key Figures * Revenue: **₹231.38 Cr** 9M FY'26 (+21.86%) * EBITDA: ₹734.04 Cr 9M FY'26 (+12.8%) · 32.1% EBITDA margin * **PAT:** **₹7.24 Cr** Q3 FY'26 (vs. ₹5.98 Cr Q3 FY'25) · **9.3%** PAT margin (vs. 10.1% YoY) ## B. Revenue Growth * **Strong Volume-Driven Expansion:** Robust revenue growth fueled by new center ramp-up and favorable mix from high-margin genomic testing. * **Pricing Strategy:** Revenue momentum supported by launch of **high-priced new tests**, indicating value-based pricing power without broad price hikes. ## C. EBITDA & Margins * **Margin Pressure from Expansion:** Q3 EBITDA margin compression reflects front-loaded costs in new centers, partially offset by strong performance from **42 mature centers** with healthy profitability. * **Profitability Shift:** Significant decline in PAT despite revenue growth, driven by **unfavorable YoY comparison** (prior-year benefit) and investment phase costs. ## D. Balance Sheet * **Net Cash Position:** Strong liquidity with **~₹29 Cr net cash**, supported by negligible net debt and no active borrowings. --- # 2. Volume & Test Trends ## A. Key Figures * **Total Income:** **₹783.09 Mn** Q3 FY'26 (+30.3%) * Tests Performed: **2.06 Mn** Q3 FY'26 (+30.7%) · **6.18 Mn** 9M FY'26 (+27.2%) * Patients Served: 0.36M Q3 FY'26 (+23%) · 1.07M 9M FY'26 (+19.3%) * **Revenue per Patient:** **₹2,140** 9M FY'26 (from ₹2,084) * **B2C/B2B Mix:** **92–93% B2C**, **7–8% B2B** ## B. Test Volume Growth * **Volume-Led Expansion:** 22% nine-month revenue growth was entirely driven by volume gains, with **no price increases** and strong contributions from genomic testing. * **GLP-1 Drug Trend Emerging:** Rising prescriptions for GLP-1 agonists like Semaglutide noted, but **direct impact on test volumes remains unquantifiable** due to lack of data. ## C. Revenue per Patient * **ARPU Uplift Achieved:** Revenue per patient rose despite margin pressure, reflecting **favorable mix and pricing discipline** in existing markets. * **New Market Potential:** Northeast regions show early promise of reaching **Kolkata-level revenue per patient** over time, despite initial discounting. ## D. B2C & B2B Mix * **B2C Dominance with B2B Stability:** B2C remains core at ~93%, while B2B has **stabilized above 7%**, reversing prior decline trends. * **Organized Penetration Opportunity:** Eastern India’s fragmented landscape—dominated by unorganized players—positions **Suraksha as the key organized disruptor**. --- # 3. Expansion & Capacity ## A. Key Figures * **New Centers Commissioned:** **12** in nine months · **6** in execution phase * **Annual Expansion Target:** **12–15 centers** (ex-PPP) · **~5 large, ~10 small** per year * **Capex Guidance:** **₹70 Cr** annually for expansion · **60–70%** of current pipeline to open by end-FY26 * **Long-Term Target:** **100 centers** by FY28 ## B. New Center Rollout * **Robust Execution Pace:** Strong momentum in center rollouts with all 12 new facilities fully operational, reflecting effective deployment of the structured launch framework. * **Strategic Geographic Expansion:** Entry into **Bihar, Northeast, and new districts in West Bengal and Jharkhand** marks deliberate footprint deepening and market adjacency plays. * **Market-Led Entry Approach:** Expansion supported by **dipstick analysis** and engagement with **key opinion leaders** to validate demand, pricing, and visibility needs pre-launch. * **Targeted Launch Strategy:** Each rollout includes tailored **media events, social media campaigns, and stakeholder engagement** to accelerate market penetration. ## C. Hub-and-Spoke Model * **Model Discipline Maintained:** Growth continues to follow the **hub-and-spoke framework**, with each large center anchored by 5–6 smaller satellites, enhancing network efficiency and referral capture. ## D. FY'27 Center Targets * **Capital Efficiency Confirmed:** FY27 expansion of 12–15 centers to be executed on **flat capex**, signaling improved cost discipline or operational leverage in deployment. * **Clear Path to 100-Center Milestone:** With 18 centers in progress or added recently and sustained annual cadence, trajectory remains aligned with **100-center target by FY28**. --- # 4. Product & Segment Mix ## A. Key Figures * **Business Mix (9M):** 46% radiology · 48% pathology · 6% doctor OPD * **Genomics Revenue Run Rate:** **INR 4+ Cr** projected by FY'27 ## B. Genomics Growth * **Strategic Differentiation:** Genomics vertical (**Suraksha Sutra**) gaining clinical traction, insulating business from commoditization in routine testing. * **Growth Catalyst:** Entry into a **nascent, high-potential market** poised for **multiples-based expansion** by FY'28, with expansion planned into cancer and genetic testing. * **Market Dynamics:** **Patent expirations** expected to lower prices and boost competition, driving broader market adoption next fiscal. * **Synergy Realization:** Acquisition delivering revenue synergies via shift to **specialized fetal medicine and integrated genomics**. ## C. Radiology & Pathology * **Balanced Core Mix:** Business remains evenly split between radiology and pathology, with minor contribution from OPD services. ## D. Service Line EBITDA * **Margin Profile:** Genomics carries **higher COGS**, but current low volumes prevent material impact on overall margins. --- # 5. Technology & Innovation ## A. Key Figures * **Genomic Lab:** **First complete genomic lab in Eastern India** with cytogenetics, microarray, PCR, and NGS capabilities * **Lab Certification:** **All molecular tests CAP validated** — a first in Eastern India * **Strategic Acquisition:** **Fetomat acquisition** enabled in-house genomics and strategic foothold in preventive testing ## B. AI in Diagnostics * **Pioneering HRD Assay Development:** Advancing the **first HRD assay for ovarian cancer** under expert leadership, positioning as an innovation leader despite smaller scale. * **AI-Driven Radiology Transformation:** Deployed **AI-powered CT and MRI reporting** in partnership with United Group, significantly improving **reporting speed and turnaround time**. * **Technology Parity with National Players:** Operates on par with larger peers like Lal and Metropolis through integrated use of **genomics, digital pathology, and AI**. * **Regional TAT Advantage:** Enjoys **faster genomic testing turnaround in Eastern India** due to localized infrastructure and proximity. ## C. Genomic Capabilities * **Exclusive Regional Coverage:** Only provider of **end-to-end genomic diagnostics in Eastern and Northeastern India**, creating a defensible market position. * **Clinical Depth & Future Focus:** Genomic lab serves high-growth areas including **oncology, reproductive health, and neurology**, with preventive genomics seen as a key future driver. * **Talent-Driven Innovation:** Backed by a **team of five PhDs** and strengthened by strategic acquisition, building leadership in advanced diagnostics. ## D. R&D Leadership * **World-Class Scientific Talent:** R&D team includes **Dr. Geetashree**, renowned oral cancer expert, and **Dr. Asima Mukhopadhyay**, co-discoverer of breakthrough ovarian cancer drug **Rucaparib**. --- # 6. Risks & Margin Pressures ## A. Key Figures * **EBITDA Loss from New Centers:** **₹2 Cr** (9M) * **New Centers:** **24** opened, **18** <1 year old ## B. New Center Losses * **Margin Compression Expected:** EBITDA margins under pressure from pre-operative costs of expansion, though core centers maintain **industry-leading efficiency**. * **Growth Over Margins:** New centers are dilutive to margins but fuel **strong top-line growth momentum**. ## C. Pricing & Receivables * **Pricing Discipline Maintained:** No broad price hikes expected; selective increases only for new or repositioned tests, avoiding value-eroding discounting. * **Receivables Drive Caution:** Price and receivables challenges lead to conservative capital deployment, with **PPP centers pursued only when necessary**. * **Cost Stability Achieved:** Non-pathology volatility from silver prices has **stabilized post-correction**, while pathology contracts insulate against raw material swings. ## D. PPP Margin Risk * **Low-Margin Avoidance:** Company avoids PPP centers due to **profitability and receivables concerns**, despite volume predictability. * **Geopolitical Watch:** Management sees minimal near-term cost pressure but flags **potential risks from future Western policy changes**. --- # 7. Guidance & Outlook ## A. Key Figures * EBITDA Margin Guidance: 32% for this year (vs. initial 33–34% target) ## B. Revenue Forecast * **Resilient Demand:** Business remains insulated from current market movements, which are in early stages and not yet impactful. * **Outperformance:** Revenue growth on track to exceed 15% guidance, reflecting strong underlying momentum. ## C. Margin Recovery * **Near-Term Pressure, Long-Term Expansion:** Margin dip to 32% due to pre-operative expenses from new center ramp-ups; structural recovery expected by Q3 FY'27. * **Strategic Prioritization:** Company prioritizing **scale and economies of scale** over short-term margin optimization.